(NASDAQ: KYNB) Kyntra Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 61.11%.
Kyntra Bio's earnings in 2026 is $183,192,000.On average, 5 Wall Street analysts forecast KYNB's earnings for 2026 to be -$56,782,081, with the lowest KYNB earnings forecast at -$60,990,335, and the highest KYNB earnings forecast at -$52,762,110. On average, 5 Wall Street analysts forecast KYNB's earnings for 2027 to be -$47,234,651, with the lowest KYNB earnings forecast at -$58,926,902, and the highest KYNB earnings forecast at -$32,184,462.
In 2028, KYNB is forecast to generate -$50,239,911 in earnings, with the lowest earnings forecast at -$71,120,838 and the highest earnings forecast at -$29,378,419.